Last reviewed · How we verify
BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ
BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ is a drug. It is currently FDA-approved (first approved 1997).
Bordetella pertussis Filamentous Hemagglutinin is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its established presence in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ |
|---|---|
| Modality | Vaccine component |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks (NA)
- Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (PHASE2, PHASE3)
- Bordetella Pertussis Colonisation Challenge Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ CI brief — competitive landscape report
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ updates RSS · CI watch RSS